# Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: LUNG
Company: Pulmonx
Source: Pulmonx
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.pulmonx.com
## Summary

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025

## Article Body
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025
## Recent Company News
- 2026-06-25 13:46 EST — [Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Pulmonx
- 2026-06-25 13:46 EST — [Pulmonx to Participate in September Investor Conferences](https://biopharmsignal.com/news/LUNG/pulmonx-to-participate-in-september-investor-conferences) — Source: Pulmonx
- 2026-06-25 13:46 EST — [Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025](https://biopharmsignal.com/news/LUNG/pulmonx-announces-management-transition-and-preliminary-third-quarter-2025-revenue-reschedules-third-quarter-2025-earnings-call-to-november-12-2025) — Source: Pulmonx
- 2026-06-25 13:46 EST — [Pulmonx Reports Third Quarter 2025 Financial Results](https://biopharmsignal.com/news/LUNG/pulmonx-reports-third-quarter-2025-financial-results) — Source: Pulmonx
- 2026-06-25 13:46 EST — [Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/LUNG/pulmonx-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Pulmonx
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)